<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631239</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-NK-2015</org_study_id>
    <nct_id>NCT02631239</nct_id>
  </id_info>
  <brief_title>MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma</brief_title>
  <official_title>The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and&#xD;
      heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.&#xD;
      The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western&#xD;
      countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for&#xD;
      these patients. But the optimal treatment schedule is controversial. The previous protocols&#xD;
      usually contained high dose methotrexate, but the application of them is limited for the&#xD;
      toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In mid-2016, we had the final evaluation of the phase 2 study of MESA with sandwiched&#xD;
      radiotherapy in newly diagnosed early stage NKTCL (NCT02825147). We obtained the final&#xD;
      overall response rate of MESA with sandwiched radiotherapy, while the 2-year progression free&#xD;
      survival rate was not available at that timepoint. To make the study design of sample size&#xD;
      more accurate, we changed the primary outcome endpoint from 2-year progression free survival&#xD;
      rate to overall response rate. The change had been approved by the Ethics Committee in August&#xD;
      10, 2016. At that time, only fourteen patients were enrolled in NCT02631239.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2016</start_date>
  <completion_date type="Anticipated">July 17, 2022</completion_date>
  <primary_completion_date type="Actual">March 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>21 days after 4 cycles of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Day 1 of each course and then every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma, Nasal Type</condition>
  <arm_group>
    <arm_group_label>MESA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>1g/m2/d IV *1d</description>
    <arm_group_label>MESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>200mg/d PO *3d</description>
    <arm_group_label>ESA</arm_group_label>
    <arm_group_label>MESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40mg/d PO *3d</description>
    <arm_group_label>ESA</arm_group_label>
    <arm_group_label>MESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>2500IU/m2/d IM *1d</description>
    <arm_group_label>ESA</arm_group_label>
    <arm_group_label>MESA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>50-56Gy</description>
    <arm_group_label>ESA</arm_group_label>
    <arm_group_label>MESA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of extranodal NK/T cell lymphoma, nasal type, previously&#xD;
             untreated&#xD;
&#xD;
          -  Age 14 ~ 70 years old&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group）performance status 0~2&#xD;
&#xD;
          -  Stage I to II&#xD;
&#xD;
          -  Life expectancy&gt;6 months&#xD;
&#xD;
          -  Informed consented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy before&#xD;
&#xD;
          -  Bone marrow transplantation before&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious&#xD;
             disease&#xD;
&#xD;
          -  LVEF≤50%&#xD;
&#xD;
          -  Other uncontrollable medical condition that may that may interfere the participation&#xD;
             of the study&#xD;
&#xD;
          -  Lab at enrollment ALT or AST &gt;3*ULN, AKP or bilirubin &gt;2.5*ULN Creatinine&gt;1.5*ULN&#xD;
&#xD;
          -  Not able to comply to the protocol for mental or other unknown reasons&#xD;
&#xD;
          -  Pregnant or lactation&#xD;
&#xD;
          -  HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

